Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Nancy E Sever

Yi Gao

Bernd Liepold

Thomas Kessler

Eric Allen Schmitt

Yi Shi

Ping Gao

Carl M Knable

John B Morris

Mark Costello

Rajeev Gokhale

Drazen Kostelac

Mirko Pauli

Peter Hoelig

Karin Rosenblatt

Fatih Durak

Anna Moosmann

Ping Tong

Ulrich Westedt

Ute Lander

Jianwei Wu

Harald Hach

Peter Hölig

Adivaraha Jayasankar

Justin S Lafountaine

Rudolf Schroeder

Thomas Mueller

Weining Z Robieson

Feroz Jameel

Matthew Rosebraugh

Ehab Moussa

Sven Stodtmann

Charles S Locke

Maurizio F Facheris

Michael Simon

Brent D Sinclair

Samuel Kyeremateng

Tina Jung

Katharina Asmus

Donghua Zhu

Susan George

Marius Naris

Colleen Garrett

Constanze Obermiller

Regina Reul

Katrin Schneider

Benedikt Steitz

Michael Siimon

The present disclosure relates to compositions of levodopa 4'-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.

Pharmaceutical formulations for subcutaneous administration

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Solid antiviral dosage forms

The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

Growing community of inventors

Northbrook, IL, United States of America

Nancy E Sever